Financial Performance - The company's revenue for Q3 2022 reached ¥269,976,553.36, representing a 26.81% increase compared to the same period last year[6]. - Net profit attributable to shareholders for Q3 2022 was ¥28,214,642.45, a significant increase of 76.96% year-over-year[6]. - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥28,443,206.15, up 91.87% from the previous year[6]. - The company's basic earnings per share for Q3 2022 was ¥0.1073, an increase of 77.94% compared to the same period last year[6]. - Total operating revenue for the current period reached ¥719,049,123.81, an increase of 19.7% compared to ¥600,305,316.55 in the previous period[36]. - Net profit for the current period was ¥95,800,886.56, representing a 16.5% increase from ¥82,242,918.86 in the previous period[38]. - Basic earnings per share increased to ¥0.2310 from ¥0.2250, reflecting a growth of 2.2%[42]. Assets and Liabilities - The total assets as of the end of Q3 2022 were ¥2,437,235,242.09, reflecting a decrease of 3.46% from the end of the previous year[6]. - The company's total liabilities as of September 30, 2022, were CNY 638.11 million, down from CNY 718.97 million at the beginning of the year, indicating a reduction of about 11.2%[31]. - As of September 30, 2022, the company's total assets amounted to approximately CNY 2.44 billion, a decrease from CNY 2.52 billion at the beginning of the year[30]. - The company's cash and cash equivalents decreased to CNY 347.59 million from CNY 472.72 million at the beginning of the year, representing a decline of approximately 26.4%[30]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,532[16]. - The largest shareholder, Wang Guan Yi, holds 11.31% of the shares, equating to 29,754,138 shares[16]. - China National Investment High-tech Industry Investment Co., Ltd. holds 6.93% of the shares, totaling 18,240,000 shares[16]. - New Yu Fu Chuang Investment Co., Ltd. owns 6.04% of the shares, amounting to 15,886,000 shares[16]. - The total number of restricted shares at the beginning of the period was 32,398,266, with 44,450 shares released during the period, leaving 32,353,816 restricted shares at the end[22]. - Wang Guan Yi has 22,315,603 restricted shares, which will be released at a rate of 25% annually[19]. Cash Flow and Investments - The cash flow from operating activities for the year-to-date period was ¥109,000,962.13, down 19.18% year-over-year[6]. - The company experienced a 95% decrease in cash received from investment due to reduced minority shareholder contributions[15]. - The company incurred share-based payment expenses of CNY 20.80 million for the first three quarters of 2022 due to the implementation of the employee stock ownership plan[29]. - Cash flow from financing activities resulted in a net cash outflow of -207,658,400.75, compared to -7,009,504.51 in the previous period, indicating increased financial strain[44]. - Cash paid for dividends and interest was 160,809,712.11, significantly higher than 21,210,043.42 in the previous period, indicating increased shareholder returns[44]. Research and Development - Research and development expenses increased by 31% to ¥52,028,613.67 due to higher investment by the French subsidiary[12]. - Research and development expenses rose to ¥52,028,613.67, up 31.2% from ¥39,652,726.97 in the prior period[36]. Project Development - The company is continuing the construction of the Furu Health Technology Park project, with support from the local government[23]. - The project was previously at risk due to land use rights recovery but has now been supported for continuation[24].

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 449,072,570.45, representing a 15.92% increase compared to CNY 387,402,455.57 in the same period last year[24]. - The net profit attributable to shareholders of the listed company decreased by 22.93% to CNY 32,547,964.21 from CNY 42,229,381.30 year-on-year[24]. - Basic earnings per share decreased by 24.89% to CNY 0.1237 from CNY 0.1647 in the same period last year[24]. - The company reported a decrease in diluted earnings per share by 22.93% to CNY 0.1237 from CNY 0.1605 year-on-year[24]. - The net cash flow from operating activities fell by 53.52% to CNY 41,864,609.74, down from CNY 90,071,009.01 in the previous year[24]. - The company reported a total investment of 61.29 million yuan for the production base technology transformation project, with an actual investment of 31.86 million yuan, resulting in a surplus of 29.43 million yuan[86]. - The company reported a net profit margin improvement, with undistributed profits rising to CNY 206,767,378.45 from CNY 200,516,745.23, an increase of about 3.6%[185]. - The company's net profit for the first half of 2022 was CNY 53,252,868.49, a decrease of 11.2% compared to CNY 59,929,745.44 in the same period of 2021[188]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,430,978,502.35, a decrease of 3.71% from CNY 2,524,643,000.05 at the end of the previous year[24]. - The net assets attributable to shareholders of the listed company decreased by 0.43% to CNY 1,513,095,593.00 from CNY 1,519,561,332.55 at the end of the previous year[24]. - Cash and cash equivalents at the end of the reporting period amounted to ¥396,743,062.66, representing 16.32% of total assets, a decrease of 2.40% from the previous year[57]. - Accounts receivable increased to ¥361,397,078.38, accounting for 14.87% of total assets, up by 1.56% year-on-year[57]. - Inventory reached ¥102,536,218.44, which is 4.22% of total assets, reflecting a slight increase of 0.24% compared to the previous year[57]. - Total liabilities decreased to CNY 355,546,359.19 from CNY 400,326,828.28, reflecting a reduction of approximately 11.2%[185]. Revenue Segments - The pharmaceutical business generated revenue of 158.05 million yuan, up 11.26% year-on-year, with e-commerce channel revenue increasing by 38.83%[32]. - The medical device segment reported revenue of 38.32 million euros, a year-on-year increase of 27.65%, and net profit of 6.05 million euros, up 37.27%[36]. - The pediatric healthcare management business saw a revenue increase of 150.37% year-on-year, with three new direct-operated clinics opened in Chengdu[37]. - The revenue from medical services increased by 100.23% to ¥18,249,642.48, reflecting strong growth in this segment[51]. - The company’s international sales accounted for ¥256,042,707.11, showing a growth of 19.95% year-on-year, while domestic sales increased by 10.97%[51]. Research and Development - The company’s R&D investment rose by 6.40% to ¥48,987,756.62, indicating a continued focus on product development and innovation[51]. - The company plans to focus R&D resources on advanced diagnostic technology in the French business sector due to significant changes in the internal and industry environment[76]. Strategic Initiatives - The company is focusing on the "Love Liver for Life" project to enhance liver disease management and improve treatment rates through a collaborative model with hospitals[38]. - The company plans to promote FibroScan as a key standard in the global NASH detection field, enhancing clinical application demand[36]. - The company is committed to a full-cycle management approach in the liver disease sector, integrating diagnostics, treatment, and patient management[47]. Shareholder Information - The company held its annual shareholders' meeting on May 30, 2022, with a participation rate of 25.07%[100]. - The employee stock ownership plan includes 65 participants, holding a total of 6,718,233 shares, representing 2.55% of the company's total equity[101]. - The largest shareholder, Wang Guan Yi, holds 11.31% of the shares, totaling 29,754,138 shares[155]. - The company has a total of 32,398,266 restricted shares, accounting for 12.32% of total shares after the change[148]. Compliance and Governance - The company did not face any administrative penalties related to environmental issues during the reporting period, indicating compliance with environmental regulations[110]. - The company confirmed that it is not classified as a key pollutant discharge unit by environmental authorities, ensuring its operations are environmentally compliant[110]. - The company has committed to avoiding any activities that may lead to competition with its controlling shareholder, ensuring stable governance[115]. Risks and Challenges - The company faces risks from macroeconomic changes and external environments, including the ongoing pandemic and geopolitical tensions, and plans to enhance its core competitiveness[89]. - The procurement price of key raw materials, particularly Cordyceps sinensis, is subject to market supply and demand fluctuations, which may impact the company's gross profit margin[92]. - The medical service business currently contributes relatively low revenue and profit, with a risk of underperformance in future development due to long cultivation periods and significant policy influence[92].

Financial Performance - The company's operating revenue for 2020 was ¥807,532,608.20, representing an increase of 11.26% compared to 2019[22]. - The net profit attributable to shareholders for 2020 was ¥61,905,640.52, reflecting a growth of 54.22% year-over-year[22]. - The net profit after deducting non-recurring gains and losses was ¥68,157,758.84, up 34.62% from the previous year[22]. - The total assets at the end of 2020 amounted to ¥2,290,529,206.59, which is a 10.22% increase from the end of 2019[22]. - The net assets attributable to shareholders reached ¥1,352,027,929.99, marking a 12.39% increase compared to the previous year[22]. - The basic earnings per share for 2020 was ¥0.2415, an increase of 52.22% from ¥0.1693 in 2019[22]. - The cash flow from operating activities for 2020 was ¥200,151,631.24, showing a slight increase of 4.08% from the previous year[22]. - The total revenue for the year 2021 was approximately ¥898.48 million, representing an increase of 11.26% compared to ¥807.53 million in 2020[61]. - The company achieved operating revenue of ¥332,644,187.55 in 2021, representing a growth of 4.20% compared to the previous year[41]. - The revenue from medical devices and technology accounted for 60.75% of total revenue, amounting to ¥545.81 million, with a year-on-year growth of 14.26%[61]. - The company reported a total revenue of ¥298,177,912.14 in Q4 2021, with a net profit of ¥37,295,143.30 for the same quarter[26]. Investment and Assets - The company holds a 50.13% stake in Echosens, which generated a net profit of ¥108,139,932.58 during the reporting period, contributing to 18.94% of the company's net assets[94]. - The total investment during the reporting period was ¥30,478,301.20, a decrease of 69% compared to the previous year[103]. - The company has a remaining balance of 1,328.95 million CNY in the fundraising special account[110]. - The total fair value of financial assets at the end of the period is 431,643.802 million CNY, with a cumulative investment income of 6,836,214 CNY[107]. - The company has not identified any significant impairment risks for its overseas assets, which account for 11.20% of the company's net assets[94]. - The company has a total of ¥70,559,354.36 in restricted assets due to mortgage loans[99]. - The construction in progress decreased to ¥182,145,653.25, reflecting a decline of 3.09%[94]. Research and Development - Research and development expenses for 2021 were ¥64,792,211.85, a decrease of 1.57% compared to 2020[75]. - The total R&D investment for 2021 was ¥98,668,071.46, representing 10.98% of operating revenue[79]. - The number of R&D personnel decreased by 6.10% from 82 in 2020 to 77 in 2021[79]. - The company is currently developing an upgraded version of Fibroscan to expand its product offerings and enhance global market competitiveness[76]. - The company has completed the data modeling and patent application for the FSTM project, achieving satisfactory research results[114]. Governance and Compliance - The company emphasizes that all board members attended the meeting to review the annual report, ensuring accountability for the report's accuracy and completeness[3]. - The company has maintained a governance structure that aligns with the requirements set by the China Securities Regulatory Commission, ensuring transparency and accountability[155]. - The company has a total of 11 board members, including 4 independent directors, complying with legal and regulatory requirements[153]. - The company has a financial independence system with an independent finance department and bank accounts, ensuring no interference from major shareholders in financial decisions[162]. - The company has established various committees within the board, including a strategic development committee and an audit committee, to enhance decision-making processes[153]. - The company has ensured that all shareholders have equal rights and access to information, maintaining fairness in shareholder meetings[152]. Market Strategy and Expansion - The company is focusing on the development of chronic disease treatment opportunities, following new regulations on long-term prescriptions issued by the National Health Commission[36]. - The company is actively developing new products and expanding the application scenarios of FibroScan in the medical field[45]. - The company is focusing on enhancing brand recognition and market share for its flagship product, the Compound Turtle Shell Soft Liver Tablet[43]. - The company aims to expand its market presence in liver disease and pediatric sectors while transitioning to managed healthcare[128]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by 2025[184]. Risk Management - The company aims to enhance risk prevention by establishing a comprehensive risk control system, focusing on key areas such as drug quality management and procurement[133]. - The company faces risks from macroeconomic changes, with strategies in place to adapt to the new development pattern of domestic and international dual circulation[138]. - The company is managing the risk of raw material price fluctuations, particularly for winter worm grass, which significantly impacts production costs[142]. - The company is aware of the potential underperformance of new business developments in medical services and is actively optimizing its business models[143]. Human Resources and Remuneration - The total remuneration paid to directors, supervisors, and senior management in 2021 amounted to 6.7425 million yuan[200]. - The remuneration for directors and supervisors is determined based on performance, capability, and position level, and is approved by the board and supervisory committee[200]. - The company has established a performance evaluation scheme for senior management approved by the chairman[200]. - The company has increased its workforce by incorporating new talent and focusing on training and performance assessment[57]. Social Responsibility and Community Engagement - The company is committed to supporting social medical enterprises and improving the policy environment for their development[40]. - The company is focusing on integrating global resources to support the "Healthy China" strategy, providing comprehensive and convenient medical services[128].

Financial Performance - The company's revenue for Q1 2022 was ¥209,134,132.83, representing an increase of 18.29% compared to ¥176,794,390.54 in the same period last year[3]. - Net profit attributable to shareholders decreased by 31.21% to ¥8,643,617.12 from ¥12,564,357.82 year-on-year[3]. - Basic and diluted earnings per share fell by 32.86% to ¥0.0329 from ¥0.0490 in the same period last year[3]. - The company achieved total operating revenue of RMB 209,134,132.83, an increase of 18.29% compared to the same period last year[21]. - The net profit attributable to shareholders was RMB 8,643,617.12, a decrease of 31.21% year-on-year[21]. - Net profit for the period was $14,911,132.63, a decrease of 2.9% from $15,349,348.79 in the same period last year[36]. - Earnings attributable to the parent company were $8,643,617.12, down 31.3% from $12,564,357.82 year-over-year[36]. Cash Flow and Assets - The net cash flow from operating activities was ¥37,137,059.96, down 3.93% from ¥38,658,176.28 in the previous year[3]. - Cash and cash equivalents at the end of the period were RMB 415,122,602.92, down from RMB 472,723,681.20 at the beginning of the year[23]. - The total assets amounted to RMB 2,513,210,029.65, slightly down from RMB 2,524,643,000.05[26]. - The company reported accounts receivable of RMB 310,996,165.54, a decrease from RMB 336,049,174.66[26]. - Inventory at the end of the period was RMB 92,101,983.23, down from RMB 100,494,780.87[26]. - The ending balance of cash and cash equivalents is ¥415,122,602.92, down from ¥437,228,786.92, a decrease of 5.1%[46]. Expenses and Liabilities - Total operating costs amounted to $185,038,994.01, up from $151,480,421.08, reflecting a year-over-year increase of 22.1%[33]. - Research and development expenses increased to $20,806,658.60, compared to $17,073,727.75, representing a growth of 22.3%[33]. - Total liabilities decreased to $696,946,707.47 from $718,966,748.86, a reduction of 3.1%[32]. - The company reported a decrease in accounts payable from $61,122,672.85 to $56,589,566.72, a decline of 7.5%[32]. Investments and Growth - The company plans to increase R&D investments, as indicated by a 57% rise in cash paid for acquiring fixed assets and intangible assets[7]. - The company plans to continue expanding its market presence and developing new products[21]. - The company has implemented an employee stock ownership plan to enhance employee motivation[21]. Other Financial Metrics - The company reported a cash flow impact from exchange rate changes of -¥4,947,509.02, compared to -¥10,061,201.59 in the previous period, showing an improvement[46]. - Other comprehensive income after tax showed a loss of $14,181,240.25, compared to a loss of $17,862,604.05 in the previous year[36]. - The decline in net profit was primarily due to the amortization of share-based payment expenses amounting to RMB 8,367,000[21]. - The company reported a 125% increase in minority shareholders' profit due to the performance growth of its French subsidiary[7].

Financial Performance - The company's revenue for Q3 2021 was ¥212,902,860.98, representing a year-over-year increase of 7.78%[5] - The net profit attributable to shareholders for Q3 2021 was ¥15,944,353.52, up 4.25% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 4.44% to ¥14,824,148.73 in Q3 2021[5] - Total operating revenue for the third quarter reached CNY 600,305,316.55, an increase of 7.3% compared to CNY 560,002,146.97 in the same period last year[34] - The net profit attributable to the parent company increased to CNY 543,907,951.37 from CNY 485,734,216.55, marking an increase of about 11.9%[33] - The net profit for the current period is 82,242,918.86, a significant increase from 35,724,203.93 in the previous period, representing a growth of approximately 130.0%[37] - The total profit for the current period is 111,707,447.23, compared to 48,074,169.01 in the previous period, indicating an increase of about 132.0%[37] - The operating profit for the current period is 110,021,897.96, up from 52,403,542.65, reflecting a growth of approximately 109.0%[37] - The basic and diluted earnings per share for the current period are both 0.2250, compared to 0.1191 in the previous period, marking an increase of about 89.0%[40] - The total comprehensive income for the current period is 88,234,108.27, compared to 48,771,803.91 in the previous period, representing an increase of approximately 81.0%[40] Assets and Liabilities - The total assets at the end of Q3 2021 reached ¥2,403,782,752.45, reflecting a 4.94% increase from the end of the previous year[5] - The company's total assets increased to CNY 2,403,782,752.45 from CNY 2,290,529,206.59, representing a growth of approximately 4.9%[33] - Total liabilities slightly decreased to CNY 674,999,598.11 from CNY 675,015,301.61, showing a marginal decline[33] - The company reported a decrease in accounts payable to CNY 59,005,862.16 from CNY 51,988,552.20, indicating a reduction of approximately 10.5%[30] - Deferred income increased to CNY 385,912,968.05 from CNY 383,139,386.91, showing a slight increase of about 0.7%[30] Cash Flow - The company reported a net cash flow from operating activities of ¥134,860,826.90, which is a 17.11% increase year-to-date[5] - The cash flow from operating activities for the current period is 134,860,826.90, compared to 115,160,914.31 in the previous period, showing an increase of approximately 17.0%[43] - The cash flow from investing activities shows a net outflow of -189,385,538.97, compared to -20,797,926.51 in the previous period, indicating a significant increase in investment expenditures[43] - The cash flow from financing activities resulted in a net outflow of -7,009,504.51, compared to an inflow of 17,476,210.87 in the previous period, reflecting a change in financing strategy[46] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,685[13] - The company has implemented an employee stock ownership plan, transferring 6,718,233 shares (2.55% of total shares) to the plan's account[23] - The company plans to repurchase shares with a total amount not less than RMB 20 million and not exceeding RMB 30 million, with a repurchase price capped at RMB 11 per share[22] - The total number of restricted shares held by major shareholders at the end of the period was 32,608,816, with no shares released during the current period[19] - The company has not yet implemented the share repurchase plan as of the report date, but intends to proceed based on market conditions[22] - The company reported a total of 8,115,700 shares held by a major shareholder through a credit trading account[16] - The company’s major shareholder, Wang Guanyi, holds 22,315,603 restricted shares, which are subject to a 25% annual release[19] - The company’s stock is not a financing margin target, and major shareholders have varying levels of stock held through different accounts[16] Expenses - The company's trading financial assets increased significantly to RMB 174,800,000 from RMB 48,000,000, marking a growth of 264.2%[24] - Accounts receivable rose to RMB 300,783,706.97 from RMB 277,666,428.93, indicating an increase of about 8.3%[24] - Total operating costs decreased to CNY 489,409,362.36 from CNY 502,697,036.01, reflecting a reduction of approximately 2.4%[34] - Research and development expenses were CNY 39,652,726.97, down from CNY 48,757,234.58, indicating a decrease of about 18.5%[34] - The company’s financial expenses decreased by 146% due to exchange gains from the appreciation of the US dollar against the euro[12] - The company’s investment income surged by 2597% due to cash dividends received from investment projects[12] - The company reported a tax expense of 29,464,528.37 for the current period, compared to 12,349,965.08 in the previous period, which is an increase of approximately 139.0%[37] Cash and Cash Equivalents - As of September 30, 2021, the company's cash and cash equivalents decreased to RMB 391,010,937 from RMB 467,904,973.74 at the end of 2020, representing a decline of approximately 16.3%[24] - The company's cash and cash equivalents increased to CNY 1,046,700,889.91 from CNY 975,430,563.34, reflecting a growth of approximately 7.5%[33] - The cash and cash equivalents at the end of the period amount to 391,010,937.00, down from 412,850,379.99 in the previous period, indicating a decrease of about 5.2%[46]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥387,402,455.57, representing a 6.88% increase compared to ¥362,465,377.65 in the same period last year[25]. - The net profit attributable to shareholders for the first half of 2021 was ¥42,229,381.30, a significant increase of 177.26% from ¥15,231,051.93 in the previous year[25]. - The net profit after deducting non-recurring gains and losses was ¥38,306,527.75, up 102.25% from ¥18,940,131.56 year-on-year[25]. - The basic earnings per share for the first half of 2021 was ¥0.1647, an increase of 177.27% compared to ¥0.0594 in the same period last year[25]. - The diluted earnings per share for the first half of 2021 was ¥0.1605, which is a 170.20% increase from ¥0.0594 in the same period last year[25]. - The weighted average return on equity for the first half of 2021 was 3.08%, up from 1.16% in the previous year[25]. - The company reported a net cash flow from operating activities of ¥90,071,009.01, a slight increase of 0.71% from ¥89,432,449.93 in the previous year[25]. - The total assets at the end of the reporting period were ¥2,437,334,938.07, reflecting a 6.41% increase from ¥2,290,529,206.59 at the end of the previous year[25]. - The net assets attributable to shareholders at the end of the reporting period were ¥1,435,552,029.07, which is a 6.18% increase from ¥1,352,027,929.99 at the end of the previous year[25]. Business Operations - The company achieved operating revenue of CNY 387,402,455.57, a year-on-year increase of 6.88%[34]. - The revenue from the diagnostic equipment business reached CNY 236,236,267.45, a year-on-year growth of 9.38%[39]. - The gross profit margin for the proprietary drug business increased by 5.85% due to the ongoing transformation of the sales model[35]. - The gross profit margin for the medical equipment and technology segment was 87.63%, with a revenue increase of 9.38% to ¥236,236,267.45[54]. - The company is expanding its product offerings and applications for FibroScan, aiming for broader use in the medical field[39]. - The company has established partnerships with hospitals nationwide to enhance liver disease management services using big data and smart tools[41]. - The company continues to strengthen its brand image as a leader in liver disease treatment and diagnostics, supported by over 2,000 international publications[44]. Investments and Assets - The company has established a global strategic layout with subsidiaries in Europe, the United States, Hong Kong, and major cities in mainland China, covering over 90 countries and regions[46]. - The company holds a 50.13% stake in Echosens, with an asset scale of ¥890,269,944.82 and a net profit of ¥34,764,750.62 during the reporting period, representing 16.61% of the company's net assets[60]. - The company has a 10.25% stake in Median Technologies, with an investment balance of ¥147,868,267.92, and no dividends were received during the reporting period, accounting for 8.59% of net assets[60]. - The company holds a 7.47% stake in Theraclion, with an investment balance of ¥16,954,128.34, and no dividends were received during the reporting period, representing 0.99% of net assets[60]. - The company reported a total investment of ¥32,881,706.95 during the reporting period, reflecting a 1.36% increase compared to the same period last year[66]. - The fair value of trading financial assets increased to ¥137,100,000.00, with a purchase amount of ¥89,900,000.00 during the reporting period[73]. - The company has a total of ¥77,268,110.58 in assets restricted for bank loan collateral, including investment properties, fixed assets, and intangible assets[64]. Strategic Focus and Future Plans - The company aims to enhance its liver disease diagnostic technology, launching a series of domestically produced FibroScan products tailored to local clinical needs[45]. - The company has a comprehensive liver disease management strategy, integrating drug production, medical device development, and patient management services[49]. - The company plans to focus R&D resources on advanced diagnostic technology, shifting from the original system development plan[80]. - The company plans to optimize its business and profit models in response to national policy changes and to enhance its risk resistance and profitability through strategic acquisitions of high-quality assets related to its main business[100]. - The company aims to strengthen its core industries in traditional pharmaceuticals and equipment while focusing on the domestic market for diagnostic equipment to drive new growth momentum[101]. Shareholder and Corporate Governance - The company held its annual shareholders' meeting on May 24, 2021, with a participation rate of 25.07%[106]. - The company does not plan to distribute cash dividends or issue bonus shares for the half-year period[108]. - The company approved the 2021 employee stock ownership plan during its board and shareholder meetings, with details disclosed on April 28, 2021[109]. - The company transferred 6,718,233 shares (2.55% of total shares) to the 2021 employee stock ownership plan account from its repurchase account[111]. - The company has committed to a share lock-up period of 36 months from the date of its stock listing, during which it will not transfer or entrust others to manage its shares[120]. - The company has not faced any environmental penalties during the reporting period and complies with relevant environmental laws[115]. - The company has not experienced significant changes in the measurement attributes of its major assets during the reporting period[63]. - The company has not reported any significant impairment of its overseas assets during the reporting period[60]. - The company has not engaged in any asset or equity acquisitions or sales during the reporting period[136]. Risks and Challenges - The company faces risks from industry competition and policy changes, which may affect its market position and require strategic adjustments[96]. - The company is exposed to risks from fluctuations in the prices of key raw materials, particularly Cordyceps sinensis, which significantly impacts production costs[97]. - The overseas business of diagnostic equipment accounts for a significant portion of the company's revenue, and uncertainties from the pandemic in regions like Europe and the U.S. may adversely affect sales[101].

Financial Performance - The company's operating revenue for Q1 2021 was ¥176,794,390.54, a decrease of 13.61% compared to ¥204,653,088.89 in the same period last year[7]. - Net profit attributable to shareholders was ¥12,564,357.82, representing an increase of 18.97% from ¥10,561,335.31 year-on-year[7]. - The net cash flow from operating activities decreased by 44.45%, amounting to ¥38,658,176.28 compared to ¥69,587,236.96 in the previous year[7]. - Basic earnings per share increased to ¥0.0490, up 18.93% from ¥0.0412 in the same period last year[7]. - The total operating revenue for the first quarter of 2021 was CNY 176,794,390.54, a decrease of approximately 13.6% compared to CNY 204,653,088.89 in the same period last year[63]. - The total profit for the current period is CNY 23,225,743.92, down from CNY 31,481,816.35, a decline of approximately 26.1%[68]. - The total comprehensive income for the current period is CNY -2,513,255.26, compared to CNY 25,231,301.10 in the previous period, indicating a significant decline[71]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,264,869,967.06, a decrease of 1.12% from ¥2,290,529,206.59 at the end of the previous year[7]. - The total liabilities decreased from CNY 675,015,301.61 to CNY 651,869,317.34, reflecting a reduction of about 3.4%[57]. - The total equity attributable to shareholders of the parent company was CNY 1,351,429,680.46, slightly down from CNY 1,352,027,929.99, indicating a decrease of approximately 0.04%[57]. - The company's non-current assets totaled approximately CNY 1.30 billion, a slight decrease from CNY 1.32 billion[52]. - The company's long-term receivables decreased from CNY 5,000,000.00 to CNY 3,950,000.00, a reduction of 21%[59]. Cash Flow - Cash inflow from operating activities was 198,501,725.75, down from 237,768,054.02 in the previous period, indicating a decrease of approximately 16.4%[79]. - The cash outflow for investment activities was 56,202,914.45, significantly higher than 24,782,064.75 in the previous period, reflecting an increase of approximately 126.5%[85]. - The net cash flow from financing activities was -3,744,895.63, compared to 29,488,046.95 in the previous period, indicating a substantial decrease[85]. - The ending balance of cash and cash equivalents was 437,228,786.92, down from 378,633,506.70 in the previous period[85]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,288[11]. - The largest shareholder, Wang Guanyi, held 11.31% of the shares, totaling 29,754,138 shares[11]. Strategic Initiatives - The company is transitioning its sales strategy for liver health products, replacing the old product with a new one and expanding sales channels to e-commerce platforms[22]. - The company plans to increase investment in internet healthcare and pediatric health management services to improve profitability[25]. - The company is actively pursuing mergers and acquisitions to enhance its long-term development and balance its business segments[28]. Risks and Challenges - The company faces risks from increased industry competition and policy changes, prompting a strategic shift towards internet healthcare and chronic disease management[25]. - The fluctuation in raw material prices, particularly for key ingredients like Cordyceps, poses a risk to the company's profit margins[26]. - The foreign subsidiary's performance was negatively impacted by the COVID-19 pandemic, leading to a 72% decrease in minority shareholder profit[21]. - The company's overseas business is significantly impacted by the ongoing COVID-19 pandemic, particularly in Europe and the United States, which affects sales of medical diagnostic equipment[29]. Investment and Projects - The total amount of raised funds is RMB 55,485.82 million, with cumulative investment reaching RMB 58,367.45 million[34]. - The company has invested RMB 18,501.03 million to acquire 100% equity of the French company Echosens, achieving 100% of the planned investment[37]. - The company has also established a joint venture, Beijing Furuizhonghe Health Technology Co., Ltd., with an investment of RMB 3,100 million, achieving 100% of the planned investment[37]. - The investment in the Furuijian Health Technology Park reached RMB 16,293.53 million, exceeding the planned investment by 104.53%[37]. - The company has terminated the "Furuijian Health Technology Park" project due to changes in urban planning, with related agreements yet to be signed[33]. Operational Efficiency - The company emphasizes enhancing core competitiveness through quality improvement and innovation[29]. - The company is committed to deepening reforms to mitigate the adverse effects of external uncertainties on its development[29]. - The online medical service management system has been implemented at the "Healthy Liver for Life Management Center," indicating progress in the company's service expansion[37]. Miscellaneous - There were no non-recurring gains or losses classified as regular gains or losses during the reporting period[10]. - The company has no violations regarding external guarantees during the reporting period[43]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[44]. - The first quarter report was not audited[93].

Financial Performance - The company reported a total revenue of 256,334,867 in 2020, with no cash dividends or stock bonuses distributed to shareholders[5]. - The company's operating revenue for 2020 was ¥807,532,608.20, a decrease of 2.91% compared to ¥831,739,342.39 in 2019[20]. - Net profit attributable to shareholders for 2020 was ¥61,905,640.52, representing a 42.69% increase from ¥43,385,849.43 in 2019[20]. - The net profit after deducting non-recurring gains and losses was ¥68,157,758.84, up 117.53% from ¥31,332,525.26 in 2019[20]. - The total assets at the end of 2020 were ¥2,290,529,206.59, an increase of 1.79% from ¥2,250,226,095.08 at the end of 2019[20]. - The basic earnings per share for 2020 were ¥0.2415, a 42.65% increase from ¥0.1693 in 2019[20]. - The company's cash reserves increased by 56% due to the maturity of bank financial products and obtaining favorable bank loans[46]. - The company reported a net profit of ¥10,561,335.31 in Q1 2020, with a total operating revenue of ¥204,653,088.89 for the same quarter[23]. - The company reported a total investment of ¥98,310,000.00 in 2020, a 61.00% increase from ¥60,961,780.62 in the previous year[106]. - The company reported a distributable profit of approximately ¥485.73 million for 2020[161]. Revenue Breakdown - Revenue from proprietary drugs increased by 29.28% to ¥269,401,140.43, accounting for 33.36% of total revenue[71]. - Revenue from circulation drugs decreased by 22.88% to ¥49,823,197.37, representing 6.17% of total revenue[71]. - Revenue from equipment and technology decreased by 12.40% to ¥477,680,262.89, making up 59.15% of total revenue[71]. - Domestic revenue increased by 14.13% to ¥333,704,012.67, while foreign revenue decreased by 12.15% to ¥473,828,595.53[71]. Market and Product Development - The company is focused on expanding its market presence and developing new products, including the FibroScan and Fibrometer technologies for non-invasive liver fibrosis diagnosis[11]. - The company achieved a sales revenue of €5.98 million for FibroScan diagnostic equipment in 2020, a year-on-year increase of 32.95%[37]. - The company successfully transitioned its sales model for its main product, the soft liver pill, to a retail-focused approach in 2020[33]. - The company’s FibroScan devices have been used to diagnose millions of patients annually and are recognized by major health organizations, enhancing its market position[50]. - The company launched domestically produced FibroScan products, improving accessibility and aligning with local clinical needs, while maintaining international quality standards[51]. - The company’s medical device business covers over 90 countries and regions globally, with a focus on expanding clinical applications of FibroScan in both domestic and international markets[54]. Research and Development - Research and development (R&D) expenses for 2020 were ¥101,669,971.81, which is 12.59% of total revenue[88]. - R&D investment in 2020 decreased slightly from the previous year, with a total of ¥101,669,971.81 compared to ¥103,029,933.22 in 2019[89]. - The number of R&D personnel decreased to 82 in 2020, making up 16.14% of the total workforce[89]. - The company continues to focus on the development of the Fibroscan product line, enhancing features and introducing new products[88]. - The capitalized R&D expenses for 2020 were ¥35,845,274.48, which is 35.26% of total R&D investment[89]. Strategic Initiatives - The company has established a network of non-invasive diagnostic centers connected to its online diagnostic system, FSTM[11]. - The company is actively participating in the development of the "Internet+" medical services, which are now included in the medical insurance reimbursement scope[43]. - The company aims to establish a "managed medical" strategy focusing on a comprehensive healthcare service framework, targeting a full-cycle safe and effective medical service for the public[139]. - The company plans to enhance its "Internet + healthcare" service system, optimizing its business model centered on children's health management and chronic disease management, to drive synchronized growth in scale and efficiency[140]. - The company has established the "West China Maternal and Child Alliance" in collaboration with Sichuan University West China Second Hospital, focusing on a standardized pediatric health management system, enhancing grassroots pediatric service capabilities[38]. Risk Management - The company has no significant adverse risk factors affecting its operational, financial status, or ongoing profitability[4]. - The company emphasizes the importance of risk awareness among investors regarding forward-looking statements and future plans[4]. - The company’s future development outlook includes addressing potential risks and implementing corresponding measures[4]. - The company faces risks from industry competition and policy changes, necessitating a strategic transformation and increased investment in the Internet + healthcare sector[146]. - The company is exposed to raw material price fluctuations, particularly for winter worm and grass, which significantly impacts production costs and gross margins[149]. - The company is affected by external factors such as the ongoing COVID-19 pandemic, which impacts its overseas sales, particularly in Europe and the United States[151]. Corporate Governance - The company is committed to ensuring the accuracy and completeness of its financial reports, as stated by its management[3]. - The company has engaged Da Hua Accounting Firm for auditing services during the reporting period[19]. - The company has no major asset or equity sales during the reporting period[132]. - The company has no non-operating fund occupation by controlling shareholders or related parties during the reporting period[175]. - The company has confirmed that its controlling shareholder will not seek to become the controlling party of the company in any form[170]. Dividend Policy - The company did not distribute cash dividends, issue bonus shares, or increase share capital from capital reserves for the fiscal year 2020[157]. - The total cash dividend amount for 2020 was 0, representing 0.00% of the net profit attributable to ordinary shareholders[161]. - The company has maintained a consistent policy of not distributing cash dividends over the past three years (2018-2020)[162]. - The company emphasized the importance of sustainable development and plans to use undistributed profits for daily operations and business expansion[162]. - The company aims to enhance financial stability and risk resistance by not distributing dividends in 2020[166].

Financial Performance - Net profit attributable to shareholders was ¥15,295,056.37, representing a significant increase of 96.38% year-on-year[8] - Operating revenue for the period was ¥197,536,769.32, reflecting a growth of 4.52% compared to the same period last year[8] - Basic earnings per share were ¥0.06, doubling from the previous period[8] - The net profit after deducting non-recurring gains and losses was ¥15,512,930.11, up 99.78% year-on-year[8] - The company's net profit for the current period is CNY 16,054,164.20, an increase from CNY 11,886,523.50 in the previous period, representing a growth of approximately 35.5%[68] - Total revenue for the current period is CNY 71,443,131.70, compared to CNY 53,272,535.45 in the previous period, indicating a year-over-year increase of about 34.1%[72] - The company's net profit for the current period is 35,724,203.93, a decrease of 15.5% compared to 42,135,721.14 in the previous period[82] - The total profit for the current period is 48,074,169.01, down 26.9% from 65,705,822.20 in the previous period[82] Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,317,166,999.97, an increase of 2.97% compared to the end of the previous year[8] - The company's total current assets reached CNY 1,022,901,933.96, up from CNY 942,101,476.58, reflecting a growth of approximately 8.6%[47] - The company's total liabilities were CNY 714,200,147.04, compared to CNY 698,663,782.17 in the previous period, indicating a slight increase of approximately 2.2%[53] - The total current liabilities increased to CNY 184,701,783.12 from CNY 149,995,022.47, representing a growth of approximately 23.1%[61] Cash Flow - The net cash flow from operating activities decreased by 59.78% to ¥25,728,464.38[8] - The company reported a decrease in cash flow from operating activities by 42.43% year-to-date compared to the same period last year[8] - Operating cash inflow for the current period is CNY 624,964,421.56, a decrease of 13.9% from CNY 725,923,637.71 in the previous period[95] - Net cash flow from operating activities is CNY 115,160,914.31, down 42.5% from CNY 200,049,368.29 in the previous period[98] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,207[12] - The largest shareholder, Wang Guanyi, held 11.31% of the shares, totaling 29,754,138 shares[13] - A major shareholder, China National Investment High-tech Industry Investment Co., Ltd., has reduced its holdings by 3,360,000 shares, accounting for 1.3108% of the total share capital[28] - The company has committed to a share lock-up period of 36 months from the date of its stock listing, during which it will not transfer or manage its shares[29] Strategic Initiatives - The company plans to terminate the "Furui Health Technology Park" project due to land use rights recovery by the local government[28] - The company plans to expand its market presence and invest in new product development to drive future growth[62] - The company is investing $5 billion in new product development, focusing on AI and augmented reality technologies[110] - Market expansion efforts include entering three new countries, aiming for a 20% increase in market share by the end of the fiscal year[110] Research and Development - Research and development expenses for the current period are CNY 1,009,828.99, a substantial increase from CNY 13,552.29 in the previous period, indicating a focus on innovation[72] - Research and development expenses increased to 48,757,234.58, up 10.5% from 44,016,915.97 in the previous period[82] Compliance and Governance - The company has made commitments to avoid any business competition with its controlling shareholders and their subsidiaries, ensuring no direct or indirect competition arises[34] - The company has confirmed that its major shareholders will not seek to become controlling shareholders or engage in activities that could undermine the current control structure[34] - The company has reported ongoing compliance with its commitments regarding share repurchase and management[33] Market Performance - In the September quarter, the company achieved a record iPhone revenue of $96.77 billion, marking significant growth in the Chinese market[110] - The overall revenue for the quarter reached $123.9 billion, representing a year-over-year increase of 12%[110] - The company reported a 15% increase in active user base, reaching 1.5 billion users globally[110] - Future guidance indicates expected revenue growth of 10% for the next quarter, projecting between $130 billion and $135 billion[110] Financial Challenges - Financial expenses surged by 246% due to exchange losses from the depreciation of the US dollar against the euro[26] - The company reported a loss from investment income of CNY 413,698.94 for the current period, compared to a loss of CNY 370,678.98 in the previous period, reflecting a worsening investment performance[72] - The total assets disposal loss is CNY 774,139.79, indicating challenges in asset management[68]

Financial Performance - The company's operating revenue for the first half of 2020 was ¥362,465,377.65, a decrease of 6.03% compared to ¥385,720,035.51 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was ¥15,231,051.93, down 6.40% from ¥16,271,846.16 in the previous year[22]. - The net profit after deducting non-recurring gains and losses was ¥18,940,131.56, a decrease of 28.13% compared to ¥26,352,666.08 in the same period last year[22]. - The net cash flow from operating activities was ¥89,432,449.93, down 34.28% from ¥136,078,889.64 in the previous year[22]. - The basic earnings per share were ¥0.0594, a decrease of 6.46% from ¥0.0635 in the same period last year[22]. - The diluted earnings per share were also ¥0.0594, reflecting the same decrease of 6.46% compared to the previous year[22]. - The weighted average return on net assets was 1.16%, down from 1.21% in the previous year[22]. - Operating costs amounted to ¥103,519,015.80, down 18.00% from ¥126,246,527.99 year-on-year[67]. - Research and development expenses increased by 4.60% to ¥51,873,615.97 compared to ¥49,590,712.20 in the previous year[67]. - The company reported a net profit of CNY 8,239,983.42 from its 50.25% stake in Echosens, contributing 15.47% to its total assets[46]. Assets and Equity - The total assets at the end of the reporting period were ¥2,252,006,936.73, an increase of 0.08% from ¥2,250,226,095.08 at the end of the previous year[22]. - The net assets attributable to shareholders of the listed company were ¥1,328,255,079.29, an increase of 0.72% from ¥1,318,750,606.67 at the end of the previous year[22]. - Cash and cash equivalents at the end of the reporting period amounted to ¥386,991,632.56, making up 17.18% of total assets[76]. - Accounts receivable decreased to ¥225,023,320.09, representing 9.99% of total assets, a decline of 5.67% from the previous year[76]. - Inventory increased to ¥108,253,455.78, accounting for 4.81% of total assets, a slight decrease of 0.75%[76]. - The company’s total equity attributable to shareholders increased by 0.72% to ¥1,328,255,079.29 compared to the end of the previous year[58]. Market and Product Performance - The company's main product, Fufang Bie Jia Ruan Gan Pian, holds a market share of over 25% in the anti-liver fibrosis traditional Chinese medicine sector, with sales revenue of ¥141,689,733.10, a decrease of 2.30% from ¥145,021,456.61 in the same period last year[32][33]. - The gross profit margin for the pharmaceutical business increased by 6.77% year-on-year, indicating improved profitability despite a decline in sales revenue[33]. - The company's flagship product, the compound tortoise shell soft liver tablet, holds over 25% market share in the anti-liver fibrosis category, making it the leading brand in this field[49]. - FibroScan, a non-invasive liver fibrosis detection device, has been used to diagnose millions of patients annually and is recognized by multiple international health organizations[49]. Strategic Initiatives - The company has shifted its sales strategy from primarily public hospitals to retail channels, enhancing pricing power and profit margins amid rising raw material costs[33]. - The company is expanding its children's health management services through partnerships with leading hospitals, replicating successful models in multiple cities[38]. - The internet hospital business has been developed to provide comprehensive online medical services, effectively reducing outpatient visits and infection risks during the pandemic[39][41]. - The company plans to enhance clinical applications of FibroScan by collaborating with large hospitals and expanding its use in primary healthcare settings[52]. - The company is focused on developing a comprehensive liver disease management solution, integrating drug production, diagnostic equipment, and patient management services[53]. Challenges and Risks - The French subsidiary's net profit fell by 68.09% to ¥8,239,983.42, down from ¥25,821,534.30 in the same period last year, due to the impact of the pandemic[37]. - The company is facing increased competition in the liver disease diagnosis and treatment market, prompting a strategic shift towards internet-based medical services and pediatric health management[116]. - The company has identified risks related to the fluctuation of raw material prices, particularly for winter worm grass, which is crucial for its main product[119]. Corporate Governance and Shareholder Information - The annual shareholders' meeting had a participation rate of 28.19% on May 20, 2020[124]. - A major shareholder, China National Investment High-tech Industry Investment Co., Ltd., plans to reduce its holdings by up to 5,261,062 shares, representing 2.0524% of the total share capital[159]. - The total number of ordinary shareholders at the end of the reporting period is 36[174]. - The largest shareholder, Wang Guan Yi, holds 11.31% of the shares, totaling 29,754,138 shares[176]. - The company has no controlling shareholder due to the dispersed shareholding structure[138]. Miscellaneous - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company has not reported any significant asset or equity sales during the reporting period[110]. - The company has not undergone any bankruptcy reorganization during the reporting period[135]. - There were no significant litigation or arbitration matters during the reporting period[136]. - The semi-annual financial report has not been audited[134].